MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$1,493,788
Net Income
-$8,862,843
Net Profit Margin
-593.31%
EPS
-$0.34
Unit: Dollar
Revenue Breakdown
Gross Product Revenue
Grosstonet Adjustments
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenues
1,493,788
1,667,298
3,944,111
-
Cost of revenues
491,843
328,878
789,208
-
Gross profit
1,001,945
1,338,420
3,154,903
-
Research and development
1,053,869
1,633,518
1,599,719
1,641,586
Amortization of in-process research and development
1,720,312
1,720,312
573,438
-
General and administrative
6,149,173
26,391,101
5,720,727
3,905,961
Stock-based compensation general and administrative
3,810,665
3,788,275
4,280,227
2,889,762
Total operating expenses
12,734,019
33,533,206
12,174,111
8,437,309
Operating loss
-11,732,074
-32,194,786
-9,019,208
-8,437,309
Interest income
116,691
53,584
45,097
53,423
Gain on sale of new jersey net operating losses
-
3,833,277
-
-
Amortization of deferred financing costs
179,492
-
-
-
Interest expense
231,732
33,031
155,538
95,520
Total other income (expense), net
-294,533
3,853,830
-110,441
-42,097
Loss before income taxes
-12,026,607
-28,340,956
-9,129,649
-8,479,406
Income tax expense (benefit)
-107,347
-231,210
264,240
264,240
Net loss
-11,919,260
-28,109,746
-9,393,889
-8,743,646
Net loss attributable to non-controlling interest
-3,056,417
-6,878,606
-1,173,104
-784,358
Net loss applicable to common stockholders
-8,862,843
-21,231,140
-8,220,785
-7,959,288
Basic EPS
-0.34
-0.95
-0.38
-0.463
Diluted EPS
-0.34
-0.95
-0.38
-0.463
Basic Average Shares
26,169,589
22,376,427
21,495,274
17,180,337
Diluted Average Shares
26,169,589
22,376,427
21,495,274
17,180,337
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss applicable
to common...
-$8,862,843
(-0.83%↓ Y/Y)
Net loss
attributable to...
-$3,056,417
(-638.26%↓ Y/Y)
Net loss
-$11,919,260
(-29.50%↓ Y/Y)
Income tax expense
(benefit)
-$107,347
(-140.62%↓ Y/Y)
Gross Product Revenue
$1,708,560
Loss before income
taxes
-$12,026,607
(-34.53%↓ Y/Y)
Revenues
$1,493,788
Grosstonet Adjustments
$214,772
Operating loss
-$11,732,074
(-33.50%↓ Y/Y)
Total other income
(expense), net
-$294,533
(-94.25%↓ Y/Y)
Gross profit
$1,001,945
Interest income
$116,691
(465.45%↑ Y/Y)
Cost of revenues
$491,843
Total operating
expenses
$12,734,019
(44.90%↑ Y/Y)
Interest expense
$231,732
(34.52%↑ Y/Y)
Amortization of deferred
financing costs
$179,492
General and
administrative
$6,149,173
(38.28%↑ Y/Y)
Stock-based compensation
general and...
$3,810,665
(40.11%↑ Y/Y)
Amortization of in-process
research and development
$1,720,312
Research and development
$1,053,869
(-35.00%↓ Y/Y)
Buy us a coffee
Citius Pharmaceuticals, Inc. (CTXR)
Citius Pharmaceuticals, Inc. (CTXR)